J&J Directors Find Root Causes But Little Blame For OTC Quality Issues
This article was originally published in The Tan Sheet
A report by a Johnson & Johnson special committee finds organizational and middle management changes at the firm were the root causes of manufacturing and quality control lapses in the OTC drug business.
You may also be interested in...
FDA clarifies pre-emption on OTC labeling
Johnson & Johnson will not “shortchange” its commitment to returning its recalled consumer brands to the marketplace, Chief Financial Officer Dominic Caruso says.
Johnson & Johnson reported July 19 the first period of positive growth for its consumer unit in more than a year.